TWGL 20/20 Global Inc

Mycotopia Therapies Announces Ei.Ventures Acquires 12x12 Estate in The Sandbox in Anticipation of PSLY.COM Launch Post-Merger with Mycotopia Therapies in Q1 2022

Mycotopia Therapies Announces Ei.Ventures Acquires 12x12 Estate in The Sandbox in Anticipation of PSLY.COM Launch Post-Merger with Mycotopia Therapies in Q1 2022

Purchase to be named PSLY.COM represents the third largest land sale in the Metaverse valued at $2.2M

MIAMI, Jan. 06, 2022 (GLOBE NEWSWIRE) -- (OTC Pink: TPIA) (the “Company”), a biopharma company focused on research, technology, and the development of medical psychedelics, announced today has acquired a 12x 12 estate in The Sandbox, a virtual world where players can build, own, and monetize their gaming experiences on the Ethereum blockchain. This purchase represents the third largest land sale in the Metaverse, and is valued at $2.2M. The land will be called PSLY.COM, the name of the soon to be merged company of Ei.Ventures with Mycotopia Therapies. The transaction was the subject of a January 5, 2022 article in Forbes by A.J. Herrington titled .

After only a week on the platform, Ei.Ventures and Orthogonal Thinker CEO David Nikzad were ready to invest in a legacy project for the combined companies’ vision of psychedelic therapy and move into the Metaverse over the next 36 months, noting, “The combination of our tech, cannabis, psychedelics, outer space, and crypto related holdings will all be utilizing this exciting space. We are very excited to invite all of our portfolio companies and investors to be part of something very special.”

Ei.Ventures now owns 144 pieces of Sandbox land that make up this 12 x 12 estate. Their neighbors include noted companies like Axie Infinity, SANDBOX, Binance and many others. PSLY.COM is now right in the middle of these disruptive giants.

Nikzad adds, “As I remember my early days as an investor going to Y Combinator, it was about looking at things that were 10B disruptive. Health and Wellness is a trillion-dollar market. As we’ve now gone through COVID and are still in the craziness of it, these technologies will become much more important as communications and how financial transactions are handled is changing,” and ends with thanks to “Blockchain.com, MetaMask, NFTTRADER and all the individuals and teams, including Ei’s co-founders, that came together to execute this transaction.”

Ben Kaplan, CEO of Mycotopia Therapies said, “Virtual land sales on the Sandbox have exploded recently and total sales between 2019 and today amount to $211 million, while the 'sand' cryptocurrency is up more than 9,000% in the last year. Blockchain technology allows users to own the content they create in The Sandbox and mint it onto non-fungible tokens, or NFTs.” Mr. Kaplan continued, “Since complex networks exist in the Metaverse without any one entity having overall control, the amount of land in The Sandbox is finite. As we work toward closing our merger with Ei.Ventures, I believe this investment in the Metaverse will prove to be very beneficial for PSLY.COM shareholders.”

You can find the Offering Circular for Ei.Ventures’ Regulation A offering here /Archives/edgar/data/1823182/000110465921096304/tm2123436d1_253g2.htm. For more information on Ei.Ventures, please go to /. For media needs, please contact Susan von Seggern at ures or 213-840-0077.

About Mycotopia Therapies

Mycotopia Therapies focuses on helping you heal and reclaim your life. Your journey of healing is an understanding of the causes and works to mental wellness through psychedelic enhanced psychotherapy, integrated with a professional team of mental wellness practitioners and cutting-edge technology. Psychedelic therapy is a holistic and spiritual approach providing healing and has shown successful treatment for many years. Additional information on Mycotopia Therapies can be found on the Company’s website at: .

About Ei. Ventures

Emotional Intelligence Ventures, a company dedicated to research and production of botanical psychedelics, announced a public stock offering using the Reg A+ Framework. Ei. Ventures’ main differentiator in the space is a self-imposed directive to work exclusively with non-synthetic, plant and fungi-based ingredients for both is psychedelic and non-psychedelic products.

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in 20/20 Global, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website,

Contact for Mycotopia Therapies

Media Inquiries and Investor Relation:

Gabe Rodriguez

Email:

Phone: (623) 261-9046



EN
06/01/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on 20/20 Global Inc

 PRESS RELEASE

Emotional Intelligence Ventures and Mycotopia enter a Definitive Agree...

Emotional Intelligence Ventures and Mycotopia enter a Definitive Agreement on $382M merger transaction Entities on track to merge under PSLY.com and list on NASDAQ Stock Exchange MIAMI and MAUI, Hawaii, May 19, 2022 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc. (OTC Pink: TPIA) (the “Company”), a biopharma company focused on research, technology, and the development of medical psychedelics, announced today an update on the previously announced merger with Ei.Ventures Inc. (“Ei”). MERGER UPDATE Ei has executed a definitive agreement with Mycotopia bringing the two entities together unde...

 PRESS RELEASE

Mycotopia Therapies Inc. Update on Ei.Ventures and Strategic Investmen...

Mycotopia Therapies Inc. Update on Ei.Ventures and Strategic Investments MIAMI, May 09, 2022 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc. (OTC Pink: TPIA), a biopharma company focused on research, technology, and the development of medical psychedelics, and Ei.Ventures Inc., a technology company empowering mental wellness through psychoactive compounds, nutraceuticals and web 3.0, are pleased to announce several strategic investments to advance the combined company's business plan. Ei.Ventures completed its Regulation A+ financing round on March 22, 2022 after announcing plans to go publi...

 PRESS RELEASE

Mycotopia Therapies Partners with Public Policy Specialist Psychedelic...

Mycotopia Therapies Partners with Public Policy Specialist PsychedelicsEUROPE to Explore Opportunities in the European Market Driving factors for growth in the European psychedelics market include growing acceptance of psychedelic medicine for treating depression and increasing prevalence of depression and mental disorders MIAMI, May 02, 2022 (GLOBE NEWSWIRE) -- (OTC Pink: TPIA) (the “Company”), a biopharma company focused on research, technology, and the development of medical psychedelics, announced today a partnership with Brussels-based . Mycotopia Therapies will collaborate with P...

 PRESS RELEASE

Mycotopia Therapies Inc. To Enter $13 Billion Medicinal Mushroom Marke...

Mycotopia Therapies Inc. To Enter $13 Billion Medicinal Mushroom Market With HAVN Life Sciences' Biopharmaceuticals And Ei.Ventures MANA Products Mycotopia Therapies and Ei.Ventures are moving forward with plans to form PSLY.COM; HAVN Life Sciences' functional mushrooms will be used in PSLY.COM’s MANA products, its line of whole-plant based medicinal mushroom nutraceuticals being developed for the consumer market MIAMI, March 21, 2022 (GLOBE NEWSWIRE) -- (OTC Pink: TPIA) (the “Company”), a biopharma company focused on research, technology, and the development of medical psychedelics, a...

 PRESS RELEASE

Mycotopia Therapies, Inc. Expands Presence In The Registered Mushroom ...

Mycotopia Therapies, Inc. Expands Presence In The Registered Mushroom Sector With HAVN Life Sciences Inc. Mycotopia Therapies plans to distribute HAVN’s line of natural OTC health products currently being registered with the Jamaican Ministry of Health MIAMI, March 17, 2022 (GLOBE NEWSWIRE) -- (OTC Pink: TPIA) (the “Company”), a biopharma company focused on research, technology, and the development of medical psychedelics, announced today plans to expand its supply agreement with (CSE: HAVN) (OTC Pink: HAVLF) to include functional mushrooms, which refers specifically to varieties of m...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch